Skip to main content
20 search results for:

Alectinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 29-04-2019 | Non-small-cell lung cancer | News | Article

    ALESIA backs first-line alectinib in Asian NSCLC patients

    Previously untreated Asian patients with advanced ALK translocation-positive non-small-cell lung cancer derive a significant progression-free survival benefit from alectinib over crizotinib, indicate phase III trial results.

  2. 31-10-2018 | Non-small-cell lung cancer | News | Article

    ALESIA confirms first-line alectinib benefit in Asian advanced NSCLC patients

    The ALESIA trial comprising treatment-naïve patients with advanced anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer confirms the systemic and intracranial efficacy of alectinib over crizotinib in an Asian population.

  3. 13-06-2018 | Non-small-cell lung cancer | ASCO 2018 | Article
    News in brief

    Advanced NSCLC PFS gain with alectinib maintained with longer follow-up

    Updated results from the phase III ALEX trial show that the progression-free survival benefit conferred by alectinib over crizotinib is maintained over time in treatment-naïve patients with anaplastic lymphoma kinase alteration-positive, advanced non-small-cell lung cancer.

  4. 13-11-2017 | FDA | News | Article
    approvalsWatch

    US ALK-positive metastatic NSCLC patients may receive first-line alectinib

    Alectinib may now be given to patients with previously untreated metastatic disease with an ALK mutation confirmed by an FDA-approved test, with a recommended dosage of 600 mg twice daily.

  5. 21-06-2017 | Non-small-cell lung cancer | News | Article
    ASCO 2017

    Alectinib ‘new standard of care’ for untreated ALK-positive NSCLC

    Compared with crizotinib, alectinib significantly improves progression-free survival in treatment-naïve patients with advanced non-small-cell lung cancer harboring an anaplastic lymphoma kinase rearrangement, shows the ALEX trial.

  6. 26-05-2017 | Non-small-cell lung cancer | News | Article

    Alectinib outperforms crizotinib in Japanese patients with ALK-rearranged NSCLC

    Among Japanese patients with advanced non-small-cell lung cancer harboring anaplastic lymphoma kinase translocations, progression-free survival is significantly longer with alectinib than crizotinib, shows a head-to-head phase III trial.

  7. 29-09-2017 | Non-small-cell lung cancer | ESMO 2017 | Article
    ESMO 2017

    ALUR, ALEX results cement alectinib as advanced ALK-positive NSCLC standard of care

    The findings of the ALUR trial and of an additional analysis of the ALEX trial confirm the benefits of treatment with the second-generation anaplastic lymphoma kinase inhibitor alectinib in patients with advanced ALK -positive non-small-cell lung cancer.

  8. 11-04-2022 | ALK-mutated NSCLC | Interview | Article

    Pathologic testing for ALK and ROS1 aberrations in NSCLC

    We can also use other drugs like brigatinib, for instance, or alectinib, and the effect of those drugs can lead to other mutations.

  9. 13-01-2022 | ALK-mutated NSCLC | Adis Journal Club | Article
    Targeted Oncology

    Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

    Results Among 584 reported psychiatric AEs, 95 cases were selected as potentially treatment related, with higher reporting frequency for lorlatinib (26, 2.8%), followed by brigatinib (10, 1.2%), alectinib (18, 0.7%), ceritinib (12, 0.6%), and crizotinib (29, 0.3%).

  10. 22-12-2021 | EMA | News | Article

    Tepotinib, lorlatinib receive EMA nod

    Previously lorlatinib could only be given to patients who had either received alectinib or ceritinib as their first ALK–TKI, or crizotinib and at least one other ALK–TKI.

  11. 15-10-2019 | Non-small-cell lung cancer | News | Article

    Value of blood-based screening for ALK fusions shown in patients with NSCLC

    Blood-based next-generation sequencing can be used to identify patients with non-small-cell lung cancer and ALK fusions who will benefit from treatment with alectinib, show results of the phase II/III blood-first assay screening trial.

  12. 15-06-2020 | FDA | News | Article
    approvalsWatch

    Brigatinib indication expanded in USA

    Speaking to medwireNews , lead author of the ALTA 1L trial D Ross Camidge (University of Colorado Cancer Center, Aurora, USA) said that “brigatinib now joins alectinib as a highly efficacious next generation ALK–TKI superior to crizotinib in the first line setting.”

  13. play
    08-06-2020 | ASCO 2020 | Conference coverage | Video

    Expert highlights: Targeted therapy for ALK-, RET- and MET-driven NSCLC

    Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

  14. 08-11-2019 | Non-small-cell lung cancer | News | Article

    Ensartinib could expand treatment options for ALK-positive NSCLC

    Median progression-free survival in the total study population was 9.6 months, which compares favorably with other second- and third-generation ALK inhibitors, namely ceritinib (5.7 months) alectinib (8.3 months), and brigatinib (12.9 months).

  15. 05-03-2019 | EMA | News | Article
    approvalsWatch

    Lorlatinib given European NSCLC approval

    The recommendation for conditional marketing authorisation states that lorlatinib monotherapy may be given to patients who have progressed after first-line ALK inhibitor therapy with alectinib or ceritinib, or who have used crizotinib and at least one other ALK tyrosine kinase inhibitor.

  16. 21-09-2018 | Non-small-cell lung cancer | News | Article

    Brigatinib has intracranial activity in patients with ALK-rearranged NSCLC

    First, given the results of the ALEX trial pitting alectinib against crizotinib in the first-line , whether brigatinib is “going to have relevant activity” if it is given after alectinib remains unknown, and second, will brigatinib – and indeed lorlatinib or ensartinib – make the transition to the first-line setting just as alectinib has done, he asked.

  17. 18-01-2019 | Non-small-cell lung cancer | News | Article

    Prolonged OS possible for ALK-positive stage IV NSCLC

    Pacheco added that “the next generation ALK inhibitors we used more commonly immediately post-crizotinib were the highly CNS penetrant next-generation ALK inhibitors alectinib and brigatinib,” and many of the patients were enrolled in clinical trials.

  18. 03-12-2018 | FDA | News | Article
    approvalsWatch

    Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

    Lorlatinib can now be administered to patients with metastatic ALK translocation-positive non-small-cell lung cancer (NSCLC) who have either progressed after treatment with crizotinib and at least one other ALK inhibitor or after treatment with alectinib or ceritinib as the first ALK inhibitor.

  19. 03-10-2018 | Non-small-cell lung cancer | News | Article

    Brigatinib outplays crizotinib in ALK inhibitor-naïve advanced NSCLC

    And indeed, Camidge noted that head-to-head comparisons of brigatinib and the other next-generation ALK inhibitor with a first-line license, alectinib, are currently underway in the post-crizotinib setting, and should help build a good efficacy and safety comparison to aid physicians in deciding which drug to use.

  20. 26-07-2017 | Non-small-cell lung cancer | Editorial | Article

    Changing landscape of treatment for ALK-positive non-small cell lung cancer

    Of 43 patients with measurable intracranial disease, the ORR was 81% for alectinib compared with 50% for crizotinib.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.